Navigation Links
Cornerstone Therapeutics Announces Closing of Chiesi Transaction
Date:7/30/2009

opment programs and related trials; our future opportunities; our strategy, future operations, financial position, future revenues and projected costs; our management's prospects, plans and objectives; and any other statements about management's future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

Any statements that are not statements of historical fact (including, without limitation, statements containing the words "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "plan," "should," "target," "will," "would" and similar expressions) should also be considered to be forward-looking statements.

There are a number of important factors that could cause our actual results or events to differ materially from those indicated by such forward-looking statements, including: risks related to our ability to develop and maintain the necessary sales, marketing, supply chain, distribution and manufacturing capabilities to commercialize our products, including difficulties relating to the manufacture of Zyflo((R)) CR tablets; the possibility that the Food and Drug Administration (the FDA) will take enforcement action against us or one or more of our marketed drugs that do not have FDA-approved marketing applications; patient, physician and third-party payor acceptance of our products as safe and effective therapeutic products; our heavy dependence on the commercial success of a relatively small number of currently marketed products; our ability to maintain regulatory approvals to market and sell our products that do have FDA-approved marketing applications; our ability to enter into additional strategic licensing, collaboration or co-promotion transactions on favorable terms, if at all; our ability to maintain compliance with NASDAQ listing requirements; adverse side effects experienced by patients tak
'/>"/>

SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Cornerstone Therapeutics Inc. Announces Record Date and Meeting Date for Special Meeting of Stockholders for Vote with Respect to Charter Amendments
2. Cornerstone Therapeutics to Present at BioCenturys 2009 Future Leaders in the Biotech Industry Conference
3. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
4. Cornerstone Therapeutics to Host Quarter and Year Ended December 31, 2008 Conference Call
5. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
6. Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date
7. PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2
8. Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters
9. United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
10. Cell Therapeutics, Inc. Announces Exercise of Overallotment
11. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Bulgaria (PRWEB) August 20, 2014 ... was released today including improvements to the enterprise ... and connectors for Lucene, SOLR and Elasticsearch. This ... for this high performance triplestore – GraphDB™ was ... interested in deploying the only mature enterprise resilient ...
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets  has announced ... Global Strategic Business Report" report to their offering. ... Culture Supplies in US$ Thousands by the following Product Segments: Media, ... for the US, Canada , Japan ... , and Latin America . Annual estimates and ...
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... report to their offering. This report ... in US$ Thousands. The report provides separate comprehensive analytics for ... , Asia-Pacific , and Rest of ... 2012 through 2020. Market data and analytics are derived from ...
(Date:8/19/2014)... 19, 2014 Research and ... the "Spectroscopy Equipment and Accessories - ... their offering. This report ... and Accessories in US$ Thousands by the ... Raman Spectrometers, NMR-EPR Spectrometers, Near Infrared (NIR) ...
Breaking Biology Technology:Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Global Cell and Tissue Culture Supplies - Strategic Business Report 2014 2Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Global Spectroscopy Equipment and Accessories - Strategic Business Report 2014 2
... Jan. 2 Nektar,Therapeutics, (Nasdaq: NKTR ) President ... at the upcoming JPMorgan 26th Annual Healthcare,Conference at the ... January 8, 2008, at 4:30 p.m. Pacific Time., ... and slideshow,webcast through a link posted on the Investor ...
... Cephalon, Inc. (Nasdaq:,CEPH) today announced that it has ... Food and Drug Administration (FDA) requesting approval of,TREANDA(R) ... patients,with indolent B-cell non-Hodgkin,s lymphoma (NHL) who have ... rituximab-containing,regimen. According to the National Cancer Institute, an ...
... MYL ) today,announced that Mylan Pharmaceuticals Inc. ... Drug Administration (FDA) for its Abbreviated New Drug,Application ... Balsalazide Disodium Capsules are the generic version of ... approximately,$130.9 million for the 12 months ending Sept. ...
Cached Biology Technology:Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 2Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 3Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 4
(Date:8/20/2014)... from the University of Tbingen, Arizona State University, the ... Public Health Institute (Swiss TPH) isolated Mycobacterium pinnipedii ... least 1000 years old. The pathogen is a relative ... occasionally causes disease in humans today. These researchers assume ... Peruvian coast. "The link to sea lions was unexpected" ...
(Date:8/20/2014)... August 19, 2014 -- Bay Area Lyme Foundation, which ... simple to cure, applauds new research published in an ... Ticks and Tick-borne Diseases . The findings show ... are active throughout the year, making the threat of ... at California Department of Public Health (CDPH) Vector-borne Disease ...
(Date:8/20/2014)... -- When are athletes who have suffered concussions ready ... study has found that high school athletes who head ... days experience a significant regression in their abilities to ... regression, as seen in changes in their balance and/or ... athletes. Ten of the 12 had returned to activity ...
Breaking Biology News(10 mins):Lyme disease risk is year-round in Northwest California, according to new study 2Lyme disease risk is year-round in Northwest California, according to new study 3Recovery reversal seen in Oregon study of returning concussed athletes 2Recovery reversal seen in Oregon study of returning concussed athletes 3
... searches blood for the tiniest remnants of broken down ... up cancer activators called proteases. The results improve researchers, ... to where to look for possible indicators of early ... , the research shows previously unknown contributing factors to ...
... The cells and tissues in our bodies grow, develop ... the various microbial pathogens that invade our bodies and ... milieu. Yet the methods of culturing and studying human ... on flat impermeable surfaces. While such 2-D culturing and ...
... with a peer facing the same self-management challenges helped ... sugar levels better than those who used traditional nurse ... University of Michigan Health System. The findings, published ... showed the peer partner program resulted in lower ...
Cached Biology News:New clues to how cancer-related proteins plasmin, thrombin lose inhibition 2New clues to how cancer-related proteins plasmin, thrombin lose inhibition 3New clues to how cancer-related proteins plasmin, thrombin lose inhibition 4The world is not flat: Exploring cells and tissues in three dimensions 2The world is not flat: Exploring cells and tissues in three dimensions 3The world is not flat: Exploring cells and tissues in three dimensions 4Diabetic adults' conditions improved after phone calls with fellow patients 2Diabetic adults' conditions improved after phone calls with fellow patients 3